Endeavour Vision closes Endeavour Medtech Growth II LP at USD 375m to invest in transformative healthcare technologies
Endeavour Vision today announces the closing of Endeavour Medtech Growth II (EMG II) LP at USD 375 million in capital commitments. The fund will pursue the same strategy as its predecessor: to support growth-stage medtech and digital health innovations that advance the standard of care and bring efficiencies to healthcare systems. Both new and returning investors supported EMG II LP, including public pension funds, multi-manager funds, family offices and high-net-worth individuals. EMG II LP builds on Endeavour Vision’s two decades of healthcare investing, which to date has included over USD 500 million invested in 42 companies - 21 of which have exited via an acquisition or IPO.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005851/en/
Endeavour Vision - Supporting medtech and digital health companies to shape the healthcare systems of tomorrow (Photo: Business Wire)
The fund’s closing comes as the world begins to look towards post-pandemic life after more than 12 months in the grip of COVID-19, a crisis that has accelerated the adoption of new healthcare technologies including novel ways of delivering remote patient care. Underlying trends, such as ageing populations, chronic diseases and strained healthcare budgets will continue to fuel demand for cost-efficient solutions. Therefore, healthcare innovation is set to remain a long-term priority that is expected to generate attractive growth and a diverse set of opportunities for investors. The fund has already supported seven companies with investments totalling more than USD 100 million: IntelyCare, CeQur, Rapid Micro Biosystems, SOPHiA GENETICS, Nalu Medical, Lumeon and Relievant Medsystems.
“Governments, citizens and investors are now more aware than ever of our healthcare systems’ strategic importance and current limitations,” said Bernard Vogel, Co-Founder and Managing Partner, Endeavour Vision. “This is accelerating the demand for pioneering solutions that can deliver sustainable healthcare. As such, EMG II LP’s timing could not be better. We want to thank the fund’s investors for their confidence in our team and strategy. In backing the bright future of this fast-growing, dynamic industry, our investors will also benefit from seeing the direct impact of their investments on people’s lives.”
“As a responsible investor working on behalf of UK Local Government Pension Schemes, we focus on seeking sustainable, long-term, risk-adjusted value to the pension scheme members through opportunities that provide a positive contribution to society,” said Nicholas Hinchliffe, Investment Director, Private Equity Investments, Local Pensions Partnership Investments. “Healthcare and health technology offers such an investment profile and helps diversify our client portfolios, and by investing in this vibrant sector through Endeavour Vision’s EMG II LP, we are able to access developments in ground-breaking clinical treatments.”
Endeavour Vision is one of the largest international investment teams focused on medtech and digital health. The firm partners with game-changing companies, actively supporting them beyond capital, with strategic and operational expertise to enable their global success.
“Medical technology and digital health are truly unique within the healthcare sector because they offer the opportunity to invest in companies in the early stages of commercialisation and before major value-inflection milestones, yet still at attractive valuations.” says Damien Tappy, President and Managing Partner, Endeavour Vision. “As recognised industry experts on both sides of the Atlantic, we are excited about the massive accelerated transformation of healthcare delivery over the next decade and the leading role Endeavour Vision can play in this.”
For more information about Endeavour Vision, please see our infographic. Two summaries are also available about EMG II LP fund and its current portfolio companies.
- Ends -
About Endeavour Vision
Endeavour Vision is a venture capital and growth equity firm founded in 2000, that invests in growth-stage medtech and digital health companies in Europe and the US. Its international investment teams are based in two global healthcare hubs in Geneva, Switzerland, and Minneapolis, US. For more information and a full list of portfolio companies, visit endeavourvision.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005851/en/
Contact information
Sarbjit Kunar
sk@endeavourvision.com
+41 79 720 09 21
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Orbia Announces Cash Tender Offer for Its Outstanding Notes Due 202217.5.2021 16:46:00 EEST | Press release
Orbia Advance Corporation, S.A.B. de C.V. (“Orbia”) (BMV: ORBIA) announces that it has commenced an offer to purchase its outstanding US$750,000,000 principal amount of 4.875% Senior Notes due 2022 (CUSIP/ISIN: 59284BAB4; P57908AD0 / US59284BAB45; USP57908AD01) (the “Securities”) pursuant to an offer (the “Tender Offer”) to purchase for cash any and all of the Securities on the terms and subject to the conditions set forth in the offer to purchase, dated May 17, 2021 (the “Offer to Purchase”) and the related notice of guaranteed delivery (the “Notice of Guaranteed Delivery” and, together with the Offer to Purchase, the “Offer Documents”). The Tender Offer will expire at 5:00 p.m. (New York City time) on May 21, 2021, unless extended (such date and time, as the same may be extended, the “Expiration Date”). Securities validly tendered may be withdrawn at any time at or prior to 5:00 p.m. (New York City time) on May 21, 2021, unless extended, but not thereafter. The settlement date of the
monday.com Announces Filing of Registration Statement for Proposed Initial Public Offering17.5.2021 15:45:00 EEST | Press release
monday.com Ltd. (“monday.com”), a work operating system (Work OS) where organizations of any size can create the tools and processes they need to manage every aspect of their work, announced today it has filed a registration statement on Form F-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. monday.com intends to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “MNDY.” Goldman Sachs & Co. LLC and J.P. Morgan will act as lead book-running managers for the proposed offering, with Allen & Company LLC and Jefferies acting as joint book-running managers. William Blair, Piper Sandler, Oppenheimer & Co., Canaccord Genuity, Cowen and Needham & Company will act as co-managers for the proposed offering. The offering will be made only by means of a prospectus. Copies of t
Personalis, Inc. to Present at Biomarkers Week Online 202117.5.2021 15:01:00 EEST | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at Biomarkers Week Online 2021. The presentation, titled “ImmunoID NeXT Platform® for comprehensive tumor immunogenomics and advanced biomarker discovery,” will describe the Personalis universal cancer immunogenomics platform, ImmunoID NeXT™. Erin Newburn, MS, PhD, will present for Personalis. Dr. Newburn will provide an overview of the platform, which combines highly sensitive, exome-scale DNA and RNA sequencing with advanced analytics to provide a multidimensional view of the tumor and the tumor microenvironment (TME) from a single sample preparation. Dr. Newburn will review a case study in a cohort of 51 late-stage melanoma patients that demonstrates how the integration of neoantigen burden, HLA LOH, and Antigen Presentation Machinery (APM) mutational data formed a composite biomarker that more accurately predicted response to checkpoint blockade than other marker
FNS Globally Launches an App Service for FANTOO, a Network-Based Platform for K-Fans17.5.2021 15:00:00 EEST | Press release
FNS Co., Ltd announced the official launching of the app service of FANTOO, a global fandom network platform for Hanryu Fans, in 175 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210517005354/en/ FNS Co., Ltd launches the app service of FANTOO, a global fandom network platform for Hanryu Fans, in 175 countries. FANTOO was developed for 100 million K-Fans across the world. The FANTOO app provides a fan club creation, user reward, multi-lingual chatting & translation, a messenger with improved security, FANTOO Karaoke for live concert, artists’ live streaming, voice call and chat, and AI-based Deepfake and adult content detection. (Graphic: Business Wire) FANTOO was developed for 100 million K-Fans across the world. It was created with a goal to promote Hanryu (the Korean Wave) culture around the world and provide the users with a space for fun and interaction. The FANTOO app provides a range of services, which inc
AGCO Agriculture Foundation Presents Second Annual Award and $50,000 Grant to Global Animal Partnership17.5.2021 15:00:00 EEST | Press release
The AGCO Agriculture Foundation (AAF), a private foundation with the vision to prevent and relieve hunger through agricultural development, announced its 2020 AAF Award goes to the Global Animal Partnership (G.A.P.) along with a $50,000 grant to help small-scale farmers in North America strengthen their animal welfare practices and earn certifications for their production processes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210517005206/en/ (Photo: Business Wire) G.A.P. is one of the largest animal welfare standards and labeling organizations in North America, and its multi-level standards impact the welfare of over 416 million farm animals on more than 3,900 farms, taking into consideration each animal’s health and productivity, natural living environment and emotional well-being. While many small-scale producers are actively adopting and implementing humane practices, logistical issues and costs can serve as a barrier
Bentley and ESI Group Work Together to Refine the Flying Spur Through Sustainable Design Process17.5.2021 15:00:00 EEST | Press release
Regulatory News: ESI Group (Paris:ESI), a global player in virtual prototyping for industries, worked hand in hand with Bentley on the optimization of one of the world’s finest four door sedan, the Flying Spur. Thanks to virtual prototyping, teams have been able to eliminate noise, vibration and harshness (NVH) and reduces physical parts in test phase. Advanced virtual design processes have been used in the testing and production cycles of the third Flying Spur generation. Thanks to ESI’s virtual prototyping, a weight optimization program for the Flying Spur could be undertaken on 40 different components. The finely tuned process enabled acoustic tests for any airborne sounds filtering into the cabin to be completed, as well as any impact from the structure itself, such as tire noise. This ensured the correct soundproofing materials were deployed in the right locations around the vehicle, so passengers can enjoy the quietest cabin experience possible. These cutting-edge techniques are
Vecima Networks and Vector Technologies Enable Gigabit Services for Liberty Global17.5.2021 15:00:00 EEST | Press release
Liberty Global (NASDAQ: LBTYA, LBTYB and LBTYK), one of the world’s leading converged video, broadband and communications companies, continues the rollout of Remote PHY (R-PHY) technology in Europe, with the support of Vector Technologies and Vecima Networks Inc. (TSX: VCM). The partnership will start Liberty Global on a path to delivering 10Gbps connectivity throughout their European footprint. The jointly developed, next-generation R-PHY solution packages Vecima’s Entra ERM112 RPD (Remote PHY Device) module in Vector Technologies’ ACCERON Compact R-PHY Node. The fully interoperable solution accelerates deployment of Distributed Access Architecture (DAA) in Liberty Global's access network and enables Liberty Global to fulfil their 10G network roadmap, delivering the next great leap in speed, capacity, and low latency. “The partnership with Vecima and Vector Technologies was a natural extension of our ongoing business activities, mainly focused on our mission to create the next-generat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom